# **Consolidated Financial Statements**

(With Report of Independent Auditors Thereon)

December 31, 2020 and 2019

# HANNOVER LIFE REASSURANCE COMPANY OF AMERICA (BERMUDA) LTD. Table of Contents

Page	
Report of Independent Auditors	1
Consolidated Balance Sheets	2
Consolidated Statements of Income	3
Consolidated Statements of Comprehensive Income	4
Consolidated Statements of Changes in Shareholder's Equity	5
Consolidated Statements of Cash Flows	6
Notes to the Consolidated Financial Statements	7 - 44



#### **Report of Independent Auditors**

To Management and the Board of Directors of Hannover Life Reassurance Company of America (Bermuda) Ltd.

We have audited the accompanying consolidated financial statements of Hannover Life Reassurance Company of America (Bermuda) Ltd. and its subsidiaries (the "Company"), which comprise the consolidated balance sheets as of December 31, 2020 and 2019, and the related consolidated statements of income, comprehensive income, changes in shareholder's equity, and cash flows for the years then ended.

## Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

## Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Opinion**

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Hannover Life Reassurance Company of America (Bermuda) Ltd. and its subsidiaries as of December 31, 2020 and 2019, and the results of their operations and their cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

May 3, 2021

Tricewaterhouse Coopers LLP

**Consolidated Balance Sheets** 

As of December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	Note		2020		2019
Accepto					
Assets Cash and cash equivalents	7	\$	93,848	\$	62,372
Fixed-income securities - available for sale	6,7	Φ	3,986,473	Φ	4,146,636
Other invested assets - available for sale	6,7		79,506		71,102
Loan Receivable	5.5,6		356,579		501
Equity Securities	7		48,563		54,728
Short-term investments	, 7		613		04,720
Participating interest other companies	8		15,000		15,000
Total investments and cash under own management			4,580,582		4,350,339
Funds withheld	9		2,977,404		3,064,533
Contract deposit assets	10		293,865		289,621
Reinsurance recoverables	15		182,205		191,023
Claim recoverables	15		65,964		91,201
Derivative asset-at fair value through profit and loss	7, 11		54,877		71,884
Accounts receivable	12		777,447		775,647
Deferred acquisition costs	13		440,555		430,375
Current Tax Receivable	21		33,778		-
Other assets	14		11,176		14,434
Total assets		\$	9,417,853	\$	9,279,057
Liabilities					
Claims reserves	15	\$	1,252,310	\$	1,209,096
Benefit reserves	15 15	Ф	1,252,310	Ф	2,137,582
Contract deposit liabilities	15		2,549,501		2,137,362
Funds withheld	9		2,349,301		230,510
Derivative liability –no hedge accounting	7,11		29,117		19,166
Accounts payable	12		147,284		157,238
Deferred tax liability	21		266,559		163,139
Other liabilities	14		144,246		199,834
Loans and borrowings	16		450,500		450,500
Total liabilities			7,046,845		7,112,106
Shareholder's equity					
Authorized, issued and fully paid, 2,500,000 shares of \$1 par value each	17		2,500		2,500
Additional paid-in capital			1,483,905		1,483,905
Retained earnings			534,567		492,533
Accumulated other comprehensive income	17		350,036		188,013
Total shareholder's equity			2,371,008		2,166,951
Total liabilities and shareholder's equity		\$	9,417,853	\$	9,279,057

Consolidated Statements of Income

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	Note	 2020	2019
Gross written premium	18	\$ 1,889,888	\$ 2,084,337
Ceded written premium	22	(137,160)	(231,316)
Change unearned premium reserve - net	4.1	 (3,410)	 (500)
Net premium earned		 1,749,318	 1,852,521
Ordinary investment income	19	151,557	157,813
Realised gains on investments - net	19	82,670	20,753
Unrealised gains and (losses) on derivatives - net	19	(6,839)	8,896
Insurance derivative income	19	24,930	15,011
Other investment expenses	19	(8,780)	(6,823)
Interest income on funds withheld and contract deposits	19	179,079	147,958
Interest expense on funds withheld and contract deposits	19	 (128,304)	 (81,530)
Net investment income		294,313	 262,078
Total revenues		 2,043,631	 2,114,599
Claims and claims expenses	4.13	(2,069,990)	(1,936,809)
Change in benefit reserves	15	152,318	140,755
Commission and brokerage, change in deferred acquisition costs-Assumed	4.11	(215,054)	(250,602)
Commission and brokerage, change in deferred acquisition costs-Ceded	4.11	14,795	14,481
Administrative expenses		 (87,593)	 (86,242)
Total expenses		(2,205,524)	(2,118,417)
Other income and expenses	20	299,753	260,689
Finance costs	16	(20,102)	(19,768)
Income before taxes		117,758	237,103
Income tax expense	21	(16,624)	(50, 150)
Net income		\$ 101,134	\$ 186,953

Consolidated Statements of Comprehensive Income

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	 2020	 2019
Net income	\$ 101,134	\$ 186,953
Other comprehensive gain		
Items that may be subsequently classified to net income		
Change in fair value of fixed income securities -available-for-sale	205,092	296,210
Tax expense	 (43,069)	 (62,204)
Net change in fair value of fixed income securities-available-for-sale	 162,023	234,006
Other comprehensive gain for the year	162,023	234,006
Total comprehensive income for the year	263,157	420,959
Total comprehensive income attributable to:	 	
Equity holder of the Company	\$ 263,157	\$ 420,959

Consolidated Statements of Changes in Shareholder's Equity

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	Note	Share capital		Additional paid in capital			Retained earnings		Accumulated other comprehensive income/(loss)		otal equity
At January 1, 2019  Net income for the year  Net change in fair value of fixed	17	\$	2,500	\$	1,483,905	\$	367,533 186,953	\$	(45,993) -	\$	1,807,945 186,953
income securities available-for-sale	17		_		_		_		234,006		234,006
Dividends declared and paid during the year	17		-		-		(63,300)		-		(63,300)
IFRS 16 Adjustment (net)	4						1,347		<u> </u>		1,347
At December 31, 2019		\$	2,500	\$	1,483,905	\$	492,533	\$	188,013	\$	2,166,951
At January 1, 2020		\$	2,500	\$	1,483,905	\$	492,533	\$	188,013	\$	2,166,951
Net income for the year  Net change in fair value of fixed	17		-		-		101,134		-		101,134
income securities available-for-sale	17		-		-		-		162,023		162,023
Dividends declared and paid during the year	17						(59,100)				(59,100)
At December 31, 2020		\$	2,500	\$	1,483,905	\$	534,567	\$	350,036	\$	2,371,008

Consolidated Statements of Cash Flows

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions

		2020		2019
Cashflows from operating activities	¢.	101 124	æ	106.050
Net income	\$	101,134	\$	186,952
Adjustments for non-cash items in net income		(00.670)		(20.752)
Net realised losses on investments		(82,670) 45,047		(20,752)
Net unrealised gains on investments  Net unrealised losses on derivatives		•		44,262
Amortisation of investments		(18,091) 1,501		(23,907) 46
Amortisation of investments  Amortisation of non related to investments		5,004		5.799
Amortisation of deferred acquisition costs		6,118		7,518
Accrued interests		6,576		(632)
Changes in		0,570		(032)
Deferred acquisition costs		(15,036)		3,051
Funds withheld		84,095		161,930
Contract deposits		217		(161,028)
Accounts receivable and payables		13,034		(161,028)
Other assets and liabilities (net)				, ,
,		(51,516)		1,581
Benefit and claim reserve (net)		(80,458)		(214,385)
Tax assets and provisions for taxes		40,540		12,506
Interest payable		20,256 75,751		18,583 4,604
Cashflows from operating activities		73,731		4,004
Cashflows from (used in) investing activities				
Maturities, sales of fixed income securities-available for sale		1,478,267		1,214,714
Purchases of fixed income securities-available for sale		(1,041,441)		(1,203,916)
Changes in loans receivable		(356,579)		(501)
Changes in other invested assets		(997)		(14,999)
Cashflows from (used in) investing activities		79,250		(4,702)
Cashflows used in financing activities				
Dividends paid		(86,100)		(21,600)
Repayment of loan interest		(37,425)		(6,270)
Cashflows used in financing activities		(123,525)		(27,870)
-				<u> </u>
Cash and cash equivalents at the beginning of the period		62,372		90,340
Change in cash and cash equivalents		31,476		(27,968)
Cash and cash equivalents at the end of the period	\$	93,848	\$	62,372
Supplementary information on the cash flow statement				
Income taxes paid (on balance)	\$	-	\$	(19,000)
Income taxes reimbursed	Ψ	5,924	Ψ	30,454
Interest received		476,417		310,031
Interest paid		(317,993)		(123, 168)
Non-Cash activities during the year not included in the Statement of Cash flows:		(3.7,000)		(123, 100)
Dividends Payable		-		41,700
· - <i>y</i>				,. 00

The accompanying notes form an integral part of these financial statements.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 1. Corporate information

Hannover Life Reassurance Company of America (Bermuda) Ltd. (the "Company" and/or "HLRA Ber") was incorporated on March 3<sup>rd</sup>, 2014 under the laws of Bermuda and is licensed as a long-term insurer (Class E), under the Insurance Act 1978 of Bermuda and related regulations, to carry on business as an insurance company. The Company is a wholly owned subsidiary of Hannover Finance, Inc. which is a wholly owned subsidiary of Hannover Rückversicherung SE (the "Parent Company" or "Hannover Re SE"), a company incorporated in Germany and trading internationally under the brand name Hannover Re. Hannover Rückversicherung SE is a publicly traded company, which is majority owned (50.2%) by Talanx AG, which in turn is majority owned (with a stake of 79%) by HDI Haftpflichtverband der Deutschen Industrie V.a.G., a German mutual insurance company. The registered office is located at Canon's Court, 22 Victoria Street, Hamilton, HM12, Bermuda.

The Company reinsures life, annuity, and health insurance business written by its client companies (cedants). The risks assumed generally reflect the risks inherent in the underlying insurance policies and include mortality risk, longevity risk, morbidity risk, investment risk and lapse and surrender risk. The Company is also assuming insurance risk in alternative forms, including swap contractual form, and then transforming the risk into traditional reinsurance contracts retroceded back to affiliates. The Company may also assume credit risk in respect of its client companies.

As a result of the U.S. Tax Cuts and Jobs Act of 2017 ("TCJA"), the Company and its affiliate, HLRUS, became subject to a new base erosion minimum tax (BEAT) in 2018. In response to this exposure, the Company restructured its reinsurance treaties during 2018, to recapture all retrocessions from foreign affiliates, and the Company assumed significant blocks of business from HLRUS that HLRUS recaptured from the foreign affiliates. The Company has Certified Reinsurer status from the Florida Office of Insurance Regulation, and a number of other states within the U.S.A.

#### <u>Merger</u>

On November 13, 2020, the Company received from Hannover Finance, Inc. a 100% investment in Hannover Life Reassurance Company of America (HLRUS) and Sand Lake Re (SLRe) as an equity contribution. The value of the investment and corresponding increase in contributed capital totaled \$364 million.

As a result of the combination of companies, the 2019 financial statements have been restated to reflect the combined results of Hannover Life Reassurance Company of America, Sand Lake Re and Hannover Life Reassurance Company of America (Bermuda) (the Group companies). The transaction was accounted for as an acquisition under common control using the predecessor value method, in accordance with the requirements IFRS 10 "Consolidated Financial Statements" The consolidated results are reported using the same valuation basis as the Parent Company. There were no shares of stock issued in the transaction.

The Company's beginning surplus at January 1, 2019 has been restated to reflect the acquisition. As a result, equity has increased by \$791 thousand from the previously reported total of \$1.376 billion. Listed below are the pre-acquired separate company financial statements and adjustments for the full year ended December 31, 2019 (in thousands):

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	HLRA Ber Unconsolidated 2019		SI Re		limination Entries	_	ILRA Ber nsolidated 2019	
Balance Sheets								
Total investments and cash under own management	\$	1,082,791	\$	3,330,548	\$	(63,000)	\$	4,350,339
Funds withheld		3,341,764		3,524,569		(3,801,800)		3,064,533
Contract deposit assets		652,873		2,147,220		(2,510,472)		289,621
Deferred acquisition costs		-		159,821		270,554		430,375
Total other assets		825,596	_	2,949,600	_	(2,631,007)	_	1,144,189
Total assets		5,903,024		12,111,758		(8,735,725)		9,279,057
Claims reserves		857,354		1,006,820		(655,078)		1,209,096
Benefit reserves		1,361,119		2,343,503		(1,567,040)		2,137,582
Contract deposit liabilities		1,826,814		2,659,297		(1,941,070)		2,545,041
Total other liabilities		482,171	_	5,146,544	_	(4,408,328)	_	1,220,387
Total liabilities	\$	4,527,458	\$	11,156,164	\$	(8,571,516)	\$	7,112,106
Total shareholder's equity	\$	1,375,566	\$	955,594	\$	(164,209)	\$	2,166,951
Total liabilities and shareholder's equity	\$	5,903,024	\$	12,111,758	\$	(8,735,725)	\$	9,279,057
Income Statements								
Net premiums earned	\$	1,484,501	\$	382,121	\$	(14,101)	\$	1,852,521
Net investment income		268,125	_	92,529	_	(98,576)	_	262,078
Total revenue		1,752,626		474,650		(112,677)		2,114,599
Claims and claims expenses		(1,538,805)		(398,004)		-		(1,936,809)
Total other expenses		(12,932)		(15,904)		(152,771)		(181,608)
Total other income and expenses		36,688	_	26,626	_	177,607	_	240,921
Income before taxes		237,577	_	87,368	_	(87,841)		237,103
Net income	\$	187,664	\$	68,684	\$	(69,395)	\$	186,953

#### Covid-19

The protracted Covid-19 pandemic continues to adversely affect the profitability of the company in the early months of 2021. We anticipate negative impacts on the result for the first quarter. Overall, the volume of losses caused by Covid-19 is difficult to forecast owing to the uncertainties surrounding the further course of the pandemic.

## 2. Basis of preparation

## 2.1 Statement of compliance

These financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") and interpretations issued by the International Financial Reporting Interpretations Committee applicable to companies reporting under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board (IASB).

## 2.2 Basis of measurement

The financial statements have been prepared on the historical cost basis except for the following noted items in the balance sheet: Fixed-income securities-available for sale, Derivative receivable-at fair value through profit and loss. The balance sheet has been presented in order of decreasing liquidity.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

## 2.3 Functional and presentation currency

The financial statements are presented in United States Dollars (USD or \$), which is also the Company's functional currency.

#### 2.4 Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses shown in the Financial Statements. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Reinsurance assets and liabilities are areas involving a higher degree of judgment and where estimates are significant to the financial statements. This is disclosed further in Notes 4.5 to 4.10 of these financial statements.

#### 3. Consolidation

#### 3.1 Consolidation principles

The consolidation is carried out according to the requirements of IFRS 10 "Consolidated Financial Statements" on the basis of a consistent consolidation model for all entities that identifies control as the single basis for verifying the consolidation requirement, irrespective of whether control is substantiated in company law, contractually or economically. The accompanying consolidated financial statements include the accounts of the Company, HLRUS and SLRe.

#### 3.2 Consolidation of business transactions within the Group

Inter-company transactions, balances, income and expenses on transactions between Group companies are eliminated. Profits and losses resulting from inter-company transactions that are recognized in assets are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Parent.

#### 4. Summary of significant accounting policies

Since 2002, the standards adopted by the International Accounting Standards Board (IASB) have been referred to as "International Financial Reporting Standards (IFRS)"; the standards dating from earlier years still bear the name "International Accounting Standards (IAS)". Standards are cited in our Notes accordingly; in cases where the Notes do not make explicit reference to a particular standard, the term IFRS is used. In accordance with the exemption provided by IFRS 4, reinsurance contracts are recognized according to the pertinent provisions of United States Generally Accepted Accounting Principles (US GAAP) as applicable on the date of initial application of IFRS 4 on January 1, 2016. We cite individual insurance-specific standards of US GAAP using the designation "FASB Accounting Standards Codification (ASC)" that was valid at the time.

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

#### New accounting standards or accounting standards applied for the first time

As a consequence of the reform of interest rate benchmarks – primarily Interbank Offered Rates (IBOR) – initiated by the G-20 countries, under which the existing reference rates are to be either redefined or replace with alternative reference rates by the end of 2021, the IASB launched a two phase project.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

The "Amendments to IFRS 9, IAS 39, and IFRS 17: Interest Rate Benchmark Reform" were published in September 2019 as a product of Phase 1. The amendments to these standards were adopted in January 2020 and are effective for financial years beginning on or after January 1, 2020. The changes relate to the period until the actual interest rate benchmark transition and are intended to ensure that existing hedging relationships can continue and new ones be designate despite the anticipated replacement of various reference rates. In addition, relief is provided for testing effectiveness. Initial application of these changes had no implications for the Company in the financial year.

In 2019 the IFRS 16 Leases standard was effective for the first time and had an impact on equity of \$1.3 million. In May 2020 the IASB issued "Amendment to IFRS 16 'Leases': Covid-19-Related Rent Concessions" in order to facilitate for lessees the accounting of concessions, e.g. deferral of rent payments and rent reductions, granted in connection with the outbreak of the coronavirus pandemic. The amendment is applicable to financial years beginning on or after June 1, 2020 and was adopted in October 2020. Earlier application is permitted. The Company did not apply the amendment in the financial year.

In addition, the amendments to existing standards listed below were effective for the first time in the year under review and had no significant implications overall for the net assets, financial position or result of operations of the Company.

- Amendments to IFRS 3 "Business Combinations"
- Amendments to IAS 1 and IAS 8: Definition of Material
- Amendments to References to the Conceptual Framework in IFRS standards

#### Standards or changes in standards that have not yet entered into force or are not yet applicable

With the publication of IFRS 17 "Insurance Contracts" in May 2017, the IASB issued a standard that replaces the existing transitional arrangements of IFRS 4 and for the first time establishes a single common framework for the recognition, measurement and disclosure of insurance contracts, reinsurance contracts and investment contracts with discretionary participation features. In addition, IFRS 17 requires extensive new disclosures in the notes.

The measurement model of IFRS 17 requires entities to measure groups of insurance contracts based on estimates of discounted future cash flows with an explicit risk adjustment for non-financial risks ("fulfilment cash flows") as well as a contractual service margin, representing the expected (i.e. unearned) profit for the provision of insurance coverage in the future.

Furthermore, the standard fundamentally changes the presentation in the consolidated statement of income and introduces the new concept of insurance revenue instead of the disclosure of gross written premium. Insurance revenue is reported when it is earned by recognizing in each period the changes in the liability for providing coverage for which the insurance entity receives compensation as well as the part of the premiums that covers acquisition costs. Receipts and payments relating to savings components are not recognized as revenue or as profit or loss in the statement of income. Insurance finance income and expenses result from discounting effects and financial risks. In accordance with the transition choices offered by IFRS 17, for each portfolio of insurance contracts they may be recognized either in profit or loss in the statement of income or directly in equity.

Changes in assumptions that do not relate to interest rates or financial risks are not recognized directly in the statement of income but are booked against the contractual service margin and hence spread across the remaining coverage period. Recognition in profit or loss is only immediate in the case of those groups of insurance contracts that are expected to be loss-making. Initial application of the

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

standard was originally mandatory on a retrospective basis for annual reporting periods beginning on or after January 1, 2021.

In view of the considerable complexity of the rules and the associated implementation effort, the IASB published an exposure draft of proposed amendments to IFRS 17 in June 2019, including deferral of the date of the standard's initial application to annual reporting periods beginning on or after January 1, 2022 and other content-related changes. Based on this draft and having regard to additional content-related changes, the IASB issued "Amendments to IFRS 17" in June 2020, thereby deferring the date of initial application of the standard including the changes for another year, i.e. to financial years beginning on or after January 1, 2023.

The exemption from initial application of IFRS 9 "Financial Instruments" granted to insurance and reinsurance entities has similarly been extended until January 1, 2023, thereby continuing to facilitate first-time application of both standards at the same time. In this connection, we would also refer to our remarks on IFRS 9 in this section.

Given that the standard affects the Company's core business activity, major implications are expected for the consolidated financial statement. In view of the special significance of the new accounting rules, a multi-year implementation project was launched back in 2017 to explore the implications of the standard for the consolidated financial statement – including the interdependency with IFRS 9 – and the necessary implementation steps were defined and initiated. Based on the elaboration of the accounting foundations, the implementation of extensive adjustments to processes and systems that began in 2019 continued in the year under review. Further development and testing activities, including an analysis of the implications of the standard for Group financials, are planned for 2021. The effects on the consolidated financial statement cannot yet be quantified at the current time.

In July 2014 the IASB published the first version of IFRS 9 "Financial Instruments" (last amended in October 2017), which supersedes all previous versions of this standard and replaces the existing IAS 39 "Financial Instruments: Recognition and Measurement". The standard contains requirements governing classification and measurement, impairment based on the new expected credit loss impairment approach and general hedge accounting. The new classification requirements result in more financial instruments being measured at fair value through profit or loss. Initial mandatory application of the standard is set for annual periods beginning on or after January 1, 2018. In September 2016, however, the IASB published "Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts (Amendments to IFRS 4)" and in June 2020 "Amendments to IFRS 4: Extension of the Temporary Exemption from Applying IFRS 9". Under the deferral approach provided for in the amendments, entities whose predominant activity is issuing insurance and reinsurance contracts within the scope of IFRS 4 are granted an optional temporary exemption from recognizing their financial instruments in accordance with IFRS 9 until probable entry into force of IFRS 17 on January 1, 2023. The Company reviewed the application requirements based on the financial statement as December 31, 2015 with a positive outcome and decided to make use of the deferral approach. Since the review of the application requirements, there has been no change in business activity that would have necessitated a re-evaluation of the predominant activity.

The Company primarily anticipates implications for the classification of financial instruments. The portfolio of financial instruments to be recognized at fair value through profit or loss will increase as a consequence of the new classification rules. In addition, the Company expects the new impairment model to have implications for debt instruments.

The IFRS 9 implementation project is running parallel to and in close coordination with the IFRS 17 implementation project. Disclosures regarding the fair values of financial instruments currently in the portfolio split according to the cash flow criterion as well as disclosures about the credit risks of

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

securities that solely generate payments of principal and interest are provided in section 7 of the notes to the consolidated financial statement "Investments under own management". This information is intended to facilitate some comparability with entities that are already applying IFRS 9.

In addition to the accounting principles described above, the IASB has issued the following standards, interpretations and amendments to existing standards with possible implications for the consolidated financial statement of the Company, application of which was not yet mandatory for the year under review and which are not being applied early by the Company. Initial application of these new standards is not expected to have any significant implications for the Company's net assets, financial position or result of operations:

#### **Further IFRS Amendments and Interpretations:**

Published:	Title	Initial Application to annual periods beginning on or after the following date:
January/July 2020	Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and Classification of Liabilities as Current or Non-current – Deferral of Effective Date	January 1, 2023
May 2020	Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework	January 1, 2022
May 2020	Amendments to IAS 16 Property, Plant and Equipment: PP&E: Proceeds before Intended Use	January 1, 2022
May 2020	Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets: Onerous Contracts Costs of Fulfilling a Contract	January 1, 2022
May 2020	Annual Improvements 2018 – 2020: IFRS 1, IFRS 9, IFRS 16, IAS 41	January 1, 2022

#### 4.1 Reinsurance contracts

IFRS 4 "Insurance Contracts" represents the outcome of Phase I of the IASB project "Insurance Contracts" and served as a transitional arrangement until the IASB issued IFRS 17. IFRS 4 sets out basic principles for the accounting of insurance contracts. Underwriting business is to be subdivided into insurance and investment contracts. Contracts with a significant insurance risk are considered to be insurance contracts, while contracts without significant insurance risk are to be classified as investment contracts. The standard is also applicable to reinsurance contracts. IFRS 4 contains fundamental rules governing specific circumstances, such as the separation of embedded derivatives and unbundling of deposit components, but it does not set out any more extensive provisions relating to the measurement of insurance and reinsurance contracts. In conformity with the basic rules of IFRS 4 and the IFRS Framework, reinsurance-specific transactions therefore continue to be recognized in accordance with the pertinent provisions of US GAAP (United States Generally Accepted Accounting Principles).

The Company has certain contracts which would be classified as insurance under IFRS 4 but which do not satisfy the risk transfer requirements of FASB ASC 944–20–15 "Financial Services – Insurance". The Company also reinsures long–duration insurance contracts that are categorized by FASB ASC 944–20–15–26 to –30 "Financial Services – Insurance" as universal life–type insurance contracts. Both these types of contracts are classified as investment contracts and recognized using the "deposit accounting" method. Income and expenses on the underlying contract are recognized

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

on an accruals basis and reported net in the Statements of Income as 'other income and expenses' and 'interest income on funds withheld and contract deposits' (see Note 20). The gross balances are shown as contract deposits assets or liabilities in the Balance Sheets (Note 10 and 15).

#### (a). Premium written

Insurance contacts are classified as either "short–duration" contracts or "long–duration" contracts. The determinative criteria are, among other things, the termination opportunities available to the insurer, the period of risk protection and the scope of the services provided to the insurer in connection with the contract. Premiums from short–duration contracts are accounted for over the period of provision of insurance cover under the underlying contract. Premiums from long–duration contracts are accounted for as these become due from the policy holder. Premiums written include adjustments to premiums written in prior accounting periods. Outward reinsurance premiums are recognized as an expense in accordance with the pattern of risks retroceded.

#### (b). Unearned premium

Unearned premium is premium that has already been written but is allocated to future risk periods. Unearned premium is usually earned pro—rata over the length of the contract.

#### 4.2 Investment income and expense

Investment income comprises income from financial assets; including interest income on funds held and contract deposits, available-for-sale assets, assets at fair value through profit or loss, cash and bank deposits. Also included are net realized gains from available-for-sale assets, gains on derivatives, net realized and unrealized gains on assets at fair value through profit or loss and other investment income. Interest income on funds held represents the Company's share of investment income on funds held assets reported by the cedant. Interest income is recognized as it accrues using either the effective interest rate method or the effective yield method depending on the underlying investment terms.

Investment expenses comprise the retrocessionaires' share of interest on funds held assets, realized losses on available-for-sale assets, losses on and costs of derivatives, realized and unrealized losses on assets at fair value through profit or loss, investment management expenses and other investment expenses. The retrocessionaires' share of interest on funds held assets is recognized as it accrues using either the effective interest rate method or the effective yield method depending on the underlying investment terms.

Changes in the fair value of derivatives are included as profits or losses in the Statements of Income in the period in which they arise.

#### 4.3 Other income

Other income includes letter of credit fees received and income on deposit accounted treaties. Income on deposit accounted treaties represents the net income on treaties where the risk transfer between the ceding company and the reinsurer is of subordinate importance. The net profit is recognized on these contracts as other income over the period of the contract.

#### 4.4 Finance costs

Finance costs comprise interest payable on borrowings using the effective interest rate method and are accounted on an accrued basis.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 4.5 Non-derivative financial assets

Investments are measured in accordance with IAS 39 'Financial Instruments: Recognition and Measurement'. Purchases and sales of equities and debt securities are recognized on the settlement date, which is when all the risk and rewards of ownership of the asset are transferred.

The Company classifies investments according to the following categories: held-to-maturity, financial assets at fair value through profit or loss, loans and receivables and available-for-sale. The allocation and measurement of investments are determined by the investment intent.

The Company recognizes the purchase and sale of directly held financial assets including derivative financial instruments as at the settlement date. The recognition of fixed–income securities includes apportionable accrued interest.

#### (a). Financial assets classified as held to maturity

Financial assets held-to-maturity are comprised of non-derivative assets that entail fixed or determinable payments on a defined due date and are acquired with the intent and ability to be held until maturity. They are initially recognized at fair value and directly attributable costs. Subsequent to the initial measurement they are measured at amortized cost. The corresponding premiums or discounts are recognized in profit or forming part of the Financial Statements loss across the duration of the instruments using the effective interest rate method.

#### (b). Financial assets classified as available for sale

Financial assets classified as available for sale are carried at fair value; accrued interest is recognized in this context. Unrealized gains and losses arising out of changes in the fair value of fixed–income securities held as available for sale are recognized within accumulated other comprehensive income/(loss), a component of shareholder's equity. All financial instruments that do not satisfy the criteria for classification as held to maturity, loans and receivables, at fair value through profit and loss, or trading are allocated to the category of available for sale. The fair value of fixed–income securities is determined primarily by means of prices fixed on publicly quoted markets or exchanges on the basis of "bid" prices. If such financial assets are not quoted on public markets, the fair value is calculated on the basis of the acknowledged effective interest rate method or estimated using other financial assets with similar credit rating, duration and return characteristics. Under the effective interest rate method, the current market interest rate levels in the relevant fixed–interest–rate periods are always taken as a basis.

(c). Investment income, Realized gains and losses, Unrealized gains and losses, other investment expenses and Income/expenses on funds withheld and contract deposits

Ordinary Investment income comprises income from financial assets, including, available for sale assets, and assets/liabilities at fair value through profit and loss and time deposits. Realized gains and losses comprises of gains and losses from available for sale assets and assets/liabilities at fair value through profit and loss. Unrealized gains and losses comprises of unrealized gains and losses from available for sale assets and assets/liabilities at fair value through profit and loss. Interest income on funds withheld represents the Company's share of investment income on funds withheld assets reported by the cedant. Interest income is recognized as it accrues using either the effective interest rate method or the effective yield method depending on the underlying investment terms. Investment expenses comprise the retrocessionaires' share of interest on funds withheld assets, losses on and costs of derivatives and investment management expenses. The retrocessionaires'

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

share of interest on funds withheld assets is recognized as it accrues using either the effective interest rate method or the effective yield method depending on the underlying investment terms.

#### (d). Impairment loss and reversals

At each balance sheet date, the Company performs a review of its financial assets for impairments. Impairments on all invested assets are recognized directly in the statements of income. IAS 39 "Financial Instruments: Recognition and Measurement" contains a list of objective, substantial indications for impairments of financial assets. In the case of fixed-income securities, reference is made, in particular, to the rating of the instrument, the rating of the issuer / borrower as well as the individual market assessment in order to establish whether they are impaired. IAS 39 "Financial Instruments: Recognition and Measurement" states, that a significant or prolonged decrease in fair value below acquisition cost constitutes objective evidence of impairment. The cumulative loss – measured as the difference between the carrying amount and the current fair value, less any impairment loss on that financial asset previously recognized in profit and loss is removed from accumulated other comprehensive income/loss and recognized as a loss in the Statements of Income. If in a subsequent period the fair value of a fixed-income security -available for sale increases and the increase can be objectively related to an event occurring after the impairment loss was recognized in profit and loss, the impairment loss is reversed through profit and loss in the Statements of Income.

#### 4.6 Derivative financial instruments

The Company's derivatives are financial instruments, the fair value of which is derived from underlying instruments such as expected cash flows related to underlying insurance contracts. The Company utilizes a discounted cash flows approach using current best estimate assumptions in order to determine fair value of its derivative assets.

In accordance with IFRS 4, certain derivatives embedded in reinsurance contracts are removed from the underlying insurance contract and accounted for at fair value pursuant to IAS 39.

Certain "modified coinsurance" and "coinsurance funds held" reinsurance treaties, the terms of which include the provision that securities are held as deposits by the ceding companies and payments rendered on the basis of the income from certain securities of the ceding company, have been identified as containing embedded derivatives. It has been determined that the interest-rate risk elements are not clearly and closely related to the underlying reinsurance arrangements. Embedded derivatives consequently result solely from the credit risk of the underlying securities portfolio.

The Company calculates the fair value of the embedded derivatives using the market information available on the valuation date on the basis of a "credit spread" method. Under this method, the derivative is valued at zero on the date when the contract is concluded and its value then fluctuates over time according to changes in the credit spread of the securities.

In accordance with IAS 39, the Company classifies embedded derivatives and derivative instruments that are not accounted for as hedging instruments as held-for-trading and measures them at fair value. The fair value of derivative financial instruments is recognized within 'Derivative liability – at fair value through profit or loss' in the Balance Sheets. At inception, the fair value of these instruments is zero with fluctuations in the fair value recognized through profit or loss in the Statements of Income.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 4.7 De-recognition of financial assets and liabilities

The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all the risks and rewards of ownership and does not retain control of the financial asset. Any interest in such transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

On de-recognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and consideration received (including any new asset obtained less any new liability assumed) is recognized in profit or loss. The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.

#### 4.8 Cash and cash equivalents

Cash and cash equivalents are carried at face value. For purposes of the Statements of Cash Flows, the Company considers all time deposits with an original maturity of ninety days or less and money market funds which can be redeemed without penalty as equivalent to cash.

## 4.9 Funds withheld and contract deposits

Funds withheld are receivables due to reinsurers from their clients in the amount of their contractually withheld cash deposits; they are recognized at acquisition cost (nominal amount). Appropriate allowance is made for credit risks.

Funds withheld primarily represent the collateral contractually withheld by our cedants to cover the technical liabilities the Company has reinsured. Balances are recognized in the Balance Sheets at amortized cost.

Under this item, we report receivables and liabilities under insurance contracts that satisfy the test of a significant risk transfer to the reinsurer as required by IFRS 4 'Insurance Contracts'. IFRS 4 requires insurance contracts that transfer a significant technical risk from the ceding company to the reinsurer to be differentiated from those under which the risk transfer is of merely subordinate importance. Since the risk transfer under the affected transactions is of subordinate importance, these contracts are recognized using the "deposit accounting" method and hence eliminated from the technical account. The compensation for risk assumption booked to income under these contracts is netted under other income and expenses and interest income on funds withheld and contract deposits. The payment flows resulting from these contracts are shown in the Statements of Cash Flows under operating activities.

#### 4.10 Reinsurance recoverables

The Company uses reinsurance in the normal course of business to manage its risk exposure. Insurance ceded to a reinsurer does not relieve the Company from its obligations to policyholders. The Company remains liable to its cedants for the portion reinsured to the extent that any reinsurer does not meet its obligations for reinsurance ceded to it under the reinsurance agreements.

Reinsurance assets represent the benefit derived from reinsurance agreements in force at the reporting date, taking into account the financial condition of the reinsurer. Amounts recoverable from reinsurers are estimated in accordance with the terms of the relevant reinsurance contract.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

Reinsurance recoverables are calculated according to the contractual conditions on the basis of the gross technical reserves. Appropriate allowance is made for credit risks.

#### 4.11 Deferred acquisition costs

Deferred acquisition costs principally consist of commissions, brokerage, ceded allowance and other variable costs directly related with the acquisition or renewal of existing reinsurance contracts. These acquisition costs are capitalized and amortized over the expected period of the underlying reinsurance contracts. The Company performs loss recognition of deferred acquisition costs, on an annual basis. Loss recognition testing applies to all in–force business. If loss recognition testing indicates that the present value of future net cash flows from the business currently on the books would be insufficient to recover the deferred acquisition costs and meet the cost of insurance liabilities, the difference, if any, is charged to income as accelerated amortization of deferred acquisition costs. The Company also performs recoverability testing to ensure that expenses deferred during the current year are recoverable against future profits.

#### 4.12 Benefit reserves

Benefit reserves relate to assumed liabilities. Assumed liabilities are comprised primarily of coinsurance of Universal Life and Term Life business as well as reinsurance of mortality risk on a YRT basis. Reported IFRS benefit reserves for coinsured Universal Life business represent policyholder account values. Reported IFRS benefit reserves for Term Life and YRT business are determined using actuarial methods and represent the present value of future claims payments to cedents less the present value of future premium due from cedents and taking into consideration any initial consideration received. Reserves are based on the cedent reported data, which typically is 3 to 6 months lag, projected forward to the valuation date.

Projected claims and premium are based on best estimate assumptions with a provision for adverse deviation.

The Company establishes premium deficiency reserves if actual and anticipated experience indicates that existing policy liabilities together with the present value of future gross premiums will not be sufficient to cover the present value of future benefits, settlement and maintenance costs and to recover unamortized acquisition costs. Premium deficiency reserves are established by a charge to income, as well as a reduction in unamortized acquisition costs and, to the extent there are no unamortized acquisition costs, an increase in future policy benefits. The determination of premium deficiency is undertaken at a unit of account level. One unit of account spans across all traditional mortality solutions business while other business are tested on a more granular basis.

Because of the many assumptions and estimates used in establishing reserves and the long-term nature of the reinsurance contracts, the reserving process, while based on actuarial science, is inherently uncertain.

#### 4.13 Claims reserves

Claims reserves expense constitute payment obligations from life and accident and health policies, incurred in the statement period, but not yet been settled. They are subdivided into reserves for reinsurance losses reported by the balance sheet date and reserves for reinsurance losses that have already been incurred but not yet reported (IBNR) by the balance sheet date. The claims reserves expense are based on estimates that may diverge from the actual amounts payable. In reinsurance business, a considerable period of time may elapse between the occurrence of an insurance loss, notification by the insurer and pro-rata payment of the loss by the reinsurer. For this reason the best

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

estimate of the future settlement amount is carried. With the aid of actuarial methods, the estimates makes allowance for past experience and assumptions relating to the future development.

#### 4.14 Related party transactions

IAS 24 defines related parties, among others, as parent companies and subsidiaries, subsidiaries of a common parent company, associated companies, legal entities under the influence of management and the management of the company itself. All related party transactions have been recorded in accordance with IAS 24 and includes business both assumed and ceded under usual market conditions.

## 4.15 Loans and borrowings

Loans and borrowings are from affiliated companies which are measured at amortized costs at the balance sheet dates.

## 4.16 Contract deposits

Contract deposits are receivables and liabilities under insurance contracts that satisfy the test of a significant risk transfer to the reinsurer as required by IFRS 4 "Insurance Contracts" but fail to meet the risk transfer required by US GAAP. These contracts are recognized using the "deposit accounting" method. The compensation for risk assumption booked to income under these contracts is netted under other income and expenses and interest income in funds withheld and contract deposits.

#### 4.17 Accounts receivable

The accounts receivable under reinsurance contracts business and other receivables are carried at nominal value; value adjustments are made where necessary on the basis of a case-by-case analysis. We use adjustments accounts for value adjustments taken on reinsurance accounts receivable, while all other write-downs are booked directly against the underlying position.

#### 4.18 Loans receivable

Loans receivable are non-derivative financial instruments that include fixed or determinable due date, are not listed on an active market and are not sold at short notice. They are carried at amortized cost. Premiums or discounts are deducted or added within the statement of income using the effective interest rate method until the amount repayable becomes due. An impairment loss is taken only to the extent that repayment of a loan is unlikely or no longer expected in full amount.

#### 5. Nature and extent of risks

In the context of its business operations the Company enters into a variety of risks. These risks are deliberately accepted, steered and monitored in order to be able to act on the associated opportunities. In this context, crucial importance is attached to risk management in order to ensure that, among other things, risks to the reinsurance portfolio remain calculable and also exceptional significant losses do not have an unduly adverse impact on the results of the Company.

#### 5.1 Risk management system

The Company's risk management system is designed to be commensurate to the nature, scale and complexity of the risks inherent in the business. The Company's approach to risk management is summarized by the following key operations:

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

- Risk identification
- Risk controlling
- Risk measurement
- Risk monitoring

All stages of the risk management cycle are steered by the Company's Board of Directors and officers of the Company including the Chief Risk Officer.

## 5.2 Risk governance

The system of governance around the Company's risk management system is comprised of a local governance framework which sits within the broader Hannover Re Group Risk Management framework. The local governance framework is underpinned by the following committees:

- The Company Board of Directors
- Risk Committee
- Operational Council
- Audit Committee

The Hannover Re Group Risk Management function provides an additional level of governance that is independent of the local Company's operations.

#### 5.3 Insurance risk

#### 5.3.1 Key risks and mitigation measures

The Company's main insurance risks are:

- Mortality risk
- Morbidity Risk
- Catastrophe risk
- Lapse risk
- Interest Rate risk

The Company's exposure to insurance risk is mitigated through the existence of Underwriting Guidelines which specify limits and thresholds to ensure that risk is accepted on a basis that is in line with the Company's risk appetite.

#### Mortality risk

Mortality risk is currently the primary insurance risk and is defined as an adverse deviation in mortality rates from expected. The Company is exposed to mortality and longevity risk through the reinsurance of life and annuity insurance business from its cedants. The reinsurance structures may include traditional structures such as risk premium reinsurance and stop loss reinsurance, alongside less traditional structures such as mortality swaps. The Company's risk management system

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

mandates maximum retention limits, and has retrocession arrangements in place to accept risk in excess of the retention limit.

#### Morbidity risk

Morbidity risk is the actuarial risk that the state of health of a person is adversely impacted by illness, disease, injury or frailty and that higher costs are triggered by medical treatment, long-term care or protracted periods of disability. The Company is exposed to morbidity risk through the reinsurance of health and long-term care business. The reinsurance structures may include traditional structures such as coinsurance, risk premium reinsurance and stop loss reinsurance, alongside less traditional structures such as morbidity cost swaps. The Company's risk management system mandates exposure limits and monitoring of morbidity risks.

## Catastrophe risk

Due to the mortality exposure described in the previous section, the Company is also exposed to mortality catastrophe risk, namely pandemic risk.

#### Lapse risk

The Company's exposure to lapse risk including mass lapse risk is primarily due to its engagement in financial reinsurance and stop-loss transactions which typically relies on the persistency of the underlying business. The Company is party to a range of cash and non-cash financing structures. Treaties are structured to mitigate the extent of the Company's exposure to lapse risk.

#### Interest rate risk

Interest rate risk refers to an unfavorable change in the value of financial assets held in the portfolio due to changes in the general interest rate level. Interest rate risk arises primarily from the Company's investments in fixed-income securities. Declining interest rates lead to increases and rising interest rates lead to decreases in the fair value of the fixed-income securities.

The reinsurance contracts written by the Company define future cash flow obligations that may be assessed with a reasonable degree of actuarial certainty. It is therefore possible for the investment portfolio to be closely matched to these obligations by currency, maturity and type. The Company monitors its interest rate risk by reviewing these obligations regularly. The Company matches its interest rate risk on an economic basis. A maturity analysis of the Company's financial assets and liabilities is provided under liquidity risk in note 16.

#### 5.3.2 Sensitivity to insurance risks

The Company assesses its exposure to insurance risk through an internal economic model best estimate liability analysis, which is subsequently used as a key input for the economic balance sheet and to determine an economic capital allocation to each risk. The Company calculates best estimate liability under a Solvency II basis quarterly for Group reporting purposes and Bermuda economic balance sheet basis at least annually. The methodology and assumptions used for Group Solvency II reporting are in line with European Insurance and Occupational Pensions Authority (EIOPA) Principles.

The table below shows the sensitivity of the Company's best estimate liability as at December 31, 2020 under a range of insurance stresses.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

USD'000s	est estimate set)/liability	Increase/(decrease) in best estimate (asset)/liability	% Change
Best Estimate	\$ 2,882,754		
Risk-free yield - 50 bps	3,120,202	237,448	8.24%
Risk-free yield + 50 bps	2,688,225	(194,529)	-6.75%
Risk-free yield -100 bps	3,344,814	462,060	16.03%
Risk-free yield +100 bps	2,528,080	(354,674)	-12.30%
Mortality business: Mortality -5%	1,163,588	(1,719,166)	-59.64%
Mortality business: Mortality +5%	4,075,417	1,192,663	41.37%
Mortality business: Mortality +10%	4,852,361	1,969,607	68.32%
Mortality business: Mortality +15%	5,437,123	2,554,369	88.61%
Pandemic: Mortality +50% in the first year	3,718,077	835,323	28.98%
Pandemic: mortality +100% in the first year	4,554,156	1,671,402	57.98%
Pandemic: Mortality +400% in the first year	9,600,076	6,717,322	233.02%
Pandemic: mortality + 1.5‰ in the first year	3,833,110	950,356	32.97%
LapseMass 40% / 70% for group life business	2,849,110	(33,644)	-1.17%
Lapse -10%	2,767,118	(115,636)	-4.01%
Lapse +10%	2,943,729	60,975	2.12%
Lapse -50%	1,432,886	(1,449,868)	-50.29%
Lapse +50%	3,148,422	265,668	9.22%

#### 5.3.3 Concentrations of insurance risk

The Company defines concentration of insurance risk as the risk of exposure to increased losses associated with an inadequately diversified insurance portfolio. Exposure to concentration risk on individual lives is not material and mitigated through the Company's retention limit set forth in the underwriting guidelines.

The process for identifying and monitoring insurance risks (including concentrations) is initiated by Group Risk Management ("GRM") and conducted annually by the Company's Risk Management function. The results are codified in a central repository for systematic identification of material risks to the risk strategy including assessment of materiality, and serves as an important tool to identify and prioritize risks for monitoring and management efforts.

#### 5.4 Market risk

The Company's investment portfolio currently consists in large part of fixed-income securities, and hence default and spread risks account for the bulk of the market risk. The Company is also exposed to changes in interest rates due to the impact on liability valuations. Since asset and liability cash flows are both impacted by changes in interest rates an integrated approach is used to assess interest rate risk on the entity's net economic value. The Company minimizes interest rate risk through the matching of durations of fixed-income securities and the related insurance contracts liabilities.

The table below shows the sensitivity to changes in interest rates on the Company's fixed-income and derivatives securities investment portfolio:

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	2020				2019					
		P&L			Equity		P&L			Equity
Fixed-income securities +100 basis point shift in yield curves -100 basis point shift in yield curves	\$		- -	\$	(505,786) 144,452	\$		-	\$	(473,462) 222,776
Derivative Securities										
+100 basis point shift in yield curves	\$		-	\$	2,848	\$		-	\$	3,076
-100 basis point shift in yield curves			-		(1,501)			-		(2,199)

#### 5.5 Credit risk

In addition to credit risk within the investment portfolio, the Company is exposed to the counterparty risk of loss in value caused by the default or delay of outstanding obligations from other business partners including cedants and retrocessionaires. Counterparty exposure is assessed across the Company's asset portfolio and across reinsurance agreements and can result, for example, from a loss in future profit or recovery of initial ceding allowance on a cedant default. This risk is controlled through the Company's underwriting guidelines by the existence of maximum exposure limits per cedant.

Credit risk is minimized to retrocessionaires through the fact that assets for risk business are retained within the Company on a funds withheld basis.

Our investments entail credit risks that arise out of the risk of a failure to pay (interest and/or capital repayment) or a change in the credit status (rating downgrade) of issuers of securities. We attach equally vital importance to exceptionally broad diversification as we do credit assessment conducted on the basis of the quality criteria set out in the investment guidelines. We measure credit risks in the first place using the standard market risk components, especially the probability of default and the potential amounts of loss – making allowance for any collateral and the ranking of the individual instruments depending on their effect in each case.

We then assess the credit risk first on the level of individual securities (issues) and in subsequent steps on a combined basis on the insurer level. In order to limit the risk of counterparty default we set various limits on the insurer and issue level as well as the form of dedicated rating quotas. A comprehensive system of risk reporting ensures timely reporting to the functions entrusted with risk management.

The following table reflects the rating structure of amounts due from ceding companies, reinsurers' share of technical contract provisions, derivative receivables and fixed income securities using Standard & Poor's or A.M. Best Moody's ratings:

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

				De	cember 31, 202	0			
	AAA	AA	A	BBB	BB	В	CCC	NR	Total
Fixed-income									
securities-available-for-sale Other invested assets -	\$ 1,318,148	\$ 516,823	\$ 775,344	\$ 1,275,596	\$ 68,182	\$ 28,598	\$ 2,478	\$ 1,304	\$ 3,986,473
available-for-sale	-	-	-	-	-	-	-	79,506	79,506
Loan Receivable	-	-	-	-	-	-	-	356,579	356,579
Funds withheld	-	10,150	285,112	(72)	54,405	303	-	2,627,506	2,977,404
Reinsurance recoverables	-	12,193	346	168,270	-	-	-	1,396	182,205
Claims Recoverables	-	37,510	5,391	19,511	-	-	-	3,552	65,964
Derivative receivable, net – at									
fair value through P&L (2)	-	-	-				-	54,877	54,877
Accounts receivable	-	178,155	271,982	35,036	6,554	2,976	-	282,743	777,447
				De	cember 31, 201	9			
	AAA	AA	A	De BBB	cember 31, 201 BB	9 B	CCC	NR	Total
Fixed_income	AAA	AA	A				ccc	NR	Total
Fixed-income				BBB	ВВ	В			
Fixed-income securities-available-for-sale Other invested assets -	<b>AAA</b> \$ 1,182,332	<b>AA</b> \$ 531,502		BBB		В	\$ 3,084	NR \$ 1,919	Total \$ 4,146,636
securities-available-for-sale				BBB	ВВ	В			
securities-available-for-sale Other invested assets -				BBB	ВВ	В		\$ 1,919	\$ 4,146,636
securities-available-for-sale Other invested assets - available-for-sale				BBB	ВВ	В		\$ 1,919 71,102	\$ 4,146,636 71,102
securities-available-for-sale Other invested assets - available-for-sale Loan Receivable		\$ 531,502 - -	\$ 918,831 -	\$ 1,443,763	\$ 39,315 :	<b>B</b> \$ 25,890	\$ 3,084	\$ 1,919 71,102 501	\$ 4,146,636 71,102 501
securities-available-for-sale Other invested assets - available-for-sale Loan Receivable Funds withheld Reinsurance recoverables Claims Recoverables		\$ 531,502 - 29,530	\$ 918,831 - - 311,667	\$ 1,443,763	\$ 39,315 :	<b>B</b> \$ 25,890	\$ 3,084	\$ 1,919 71,102 501 2,666,883	\$ 4,146,636 71,102 501 3,064,534
securities-available-for-sale Other invested assets - available-for-sale Loan Receivable Funds withheld Reinsurance recoverables Claims Recoverables Derivative receivable, net – at		\$ 531,502 - - 29,530 13,890	\$ 918,831 - - 311,667 1,475	\$ 1,443,763 - (80) 175,651	\$ 39,315 :	<b>B</b> \$ 25,890	\$ 3,084	\$ 1,919 71,102 501 2,666,883 7 809	\$ 4,146,636 71,102 501 3,064,534 191,023 91,201
securities—available—for—sale Other invested assets - available-for-sale Loan Receivable Funds withheld Reinsurance recoverables Claims Recoverables		\$ 531,502 - - 29,530 13,890	\$ 918,831 - - 311,667 1,475	\$ 1,443,763 - (80) 175,651	\$ 39,315 :	<b>B</b> \$ 25,890	\$ 3,084	\$ 1,919 71,102 501 2,666,883 7	\$ 4,146,636 71,102 501 3,064,534 191,023

<sup>\*</sup> Included in the Derivative receivable, net –at fair value through P&L as December 31, 2020 is USD \$18.4 million (2019: \$25.2 million) of B36 – Derivative instruments (unbundled from insurance contracts).

## 5.6 Liquidity risk

Liquidity risk is risk of being unable to meet financial obligations when they become due. Liquidity risk is controlled through the Company's investment guidelines which stipulates minimum liquidity requirements as a proportion of the total invested portfolio. Liquidity risk arising from insurance contracts is managed through the use of financial projections and forecasts to ensure the Company is able to meet its expected liquidity requirements.

## 6. Investments under own management

Investments are classified and measured in accordance with IAS 39 "Financial Instruments: Recognition and Measurement". The Company classifies investments according to the following categories: financial assets classified as available for sale and financial assets at fair value through profit and loss. The allocation and measurement of investments are determined by the investment intent.

		20	20			20	)19		
Fixed income securities-		Amortised		Fair	-	Amortised		Fair	
Available for sale	cost		Value 1		cost			Value 1	
Due in one year	\$	67,117	\$	68,382	\$	110,813	\$	112,228	
Due after one through two years		137,009		143,200		135,090		139,056	
Due after two through three years		220,833		236,457		182,939		189,246	
Due after three through four years		208,160		228,516		241,757		252,863	
Due after four through five years		236,612		261,988		238,152		251,452	
Due after five years through ten years		1,182,593		1,328,733		1,507,456		1,603,341	
Due after more than ten years		1,461,806		1,719,197		1,455,249		1,598,450	
Total	\$	3,514,130	\$	3,986,473	\$	3,871,456	\$	4,146,636	

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

		2020			20	)19	
Other invested assets -Available	A	mortised	Fair	Δ	mortised		Fair
for sale		cost	 /alue 1		cost		Value 1
Due in one year	\$	-	\$ _	\$	250	\$	250
Due after one through two years		_	-		-		-
Due after two through three years		20,666	21,189		14,900		15,297
Due after three through four years		-	-		-		-
Due after four through five years		-	-		-		-
Due after five years through ten years		23,277	24,593		31,999		33,236
Due after more than ten years		30,570	 33,724		21,125		22,319
Total	\$	74,513	\$ 79,506	\$	68,274	\$	71,102

#### 1 Including accrued interest

The stated maturities may in individual cases diverge from the contractual maturities because borrowers may have the right to call or prepay obligations with or without penalty.

The Other invested assets –Available for Sale are with a non-related counterparty and provide cash financing to fund a portion of commissions relating to a block of annuity business. The fair value of these notes is calculated using an internal model based on changes in interest rates and credit spreads. The main risks associated with these instruments are counterparty, lapse and mortality risk.

# Amortized cost, unrealized gains and losses, accrued interest and fair value on the portfolio of investments classified as available for sale

					2020				
	Amortised	ι	Inrealised	ι	Inrealised		Accrued		
	 cost		gains		losses	_	interest		Fair value
Available for Sale Fixed income securities US treasury notes	\$ 1,090,916	\$	167,135	\$	(2,495)	\$	5,116	\$	1,260,672
Debt securities issued by semi–governmental entities Corporate securities	 366,628 2,056,586		42,095 237,029		(835) (1,390)		4,544 21,144		412,432 2,313,369
Total	\$ 3,514,130	\$	446,259	\$	(4,720)	\$	30,804	\$	3,986,473
Other invested assets	\$ 74,512	\$	4,157	\$	-	\$	837	\$	79,506
Total	\$ 74,512	\$	4,157	\$	-	\$	837	\$	79,506
	 mortised cost	Uı	nrealised gains	U	2019 nrealised losses		Accrued interest	-	air value
	 cost		guiiis	-	103303		merese		an value
Available for Sale Fixed income securities									
US treasury notes  Debt securities issued by semi–governmental entities  Corporate securities	\$ 1,012,805 390,281 2,468,370	\$	59,138 24,132 161,968	\$	(3,309) (1,026) (3,101)	\$	5,322 4,895 27,161	\$	1,073,956 418,282 2,654,398
Total	\$ 3,871,456	\$	245,238	\$	(7,436)	\$	37,378	\$	4,146,636
Other invested assets	\$ 68,274	\$	1,845	\$		\$	983	\$	71,102
Total	\$ 68,274	\$	1.845	\$		\$	983	\$	71,102

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

The carrying amounts of the fixed-income securities classified as available for sale as well as the short-term investments allocated to this category correspond to their fair values, in the case of interest-bearing assets including accrued interest.

Effective July 1st, 2021, the company entered into agreements to transfers invested assets to a third party in return for a scheduled quarterly repayment of principal and fixed interest at 2.35%. The instrument is classified as a loan receivable and collateral supporting the loan is held in trust for the benefit of the Company.

#### Rating structure of fixed income securities

					2020				
_	AAA	AA	Α	BBB	BB	В	CCC	Other	Total
Fixed-income securities-available-for-sale Other invested assets - available-for-sale	1,318,148	516,823	775,344	1,275,596	68,182	28,598	2,478	1,304 79,506	3,986,473 79,506
					2019				
	AAA	AA	Α	BBB	BB	В	ccc	Other	Total
Fixed_income securities_available_for_sale Other invested assets -	1,182,332	531,502	918,831	1,443,763	39,315	25,890	3,084	1,919	4,146,636
available-for-sale	-	-	-	-	-	-	-	71,102	71,102

The maximum credit risk of the items shown here corresponds to their carrying amounts.

#### 7. Fair value hierarchy

For the purposes of the disclosure requirements pursuant to IFRS 7 "Financial Instruments: Disclosures", the financial instruments recognized at fair value in the balance sheet are to be assigned to a three–level fair value hierarchy. This hierarchy, which reflects characteristics of the price data and inputs used for measurement purposes, is structured as follows:

- Level 1: Assets or liabilities measured at (unadjusted) prices quoted directly in active and liquid markets.
- Level 2: Assets or liabilities which are measured using observable market data and are not allocable to level 1 measurement is based, in particular, on prices for comparable assets and liabilities that are traded on active markets, prices on markets that are not considered active as well as inputs derived from such prices or market data.
- Level 3: Assets or liabilities that cannot be measured or can only be partially measured using observable market inputs. The measurement of such instruments draws principally on valuation models and methods.

The following table shows the breakdown of the financial instruments recognized at fair value into the three–level fair value hierarchy.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

		20	20		
	Level 1	 Level 2		Level 3	 Total
Cash and cash equivalents  Fixed income securities—available for sale	\$ 93,848	\$ - 3,986,473	\$	-	\$ 93,848 3,986,473
Other invested assets - available for sale Equity Securities	-	-		79,506 48,563	79,506 48,563
Short-term investments Investment in associated companies (not cons.) Derivative asset – at fair value through profit and loss	613	- - 18,350		15,000 36,527	613 15,000 54,877
Total assets carried at fair value	\$ 94,461	\$ 4,004,823	\$	179,596	\$ 4,278,880
Derivative liabilities – at fair value through profit and loss	\$ -	\$ (29,117)	\$	-	\$ (29,117)
Total liabilities carried at fair value	\$ -	\$ (29,117)	\$	-	\$ (29,117)
		20	019		
	 Level 1	 Level 2		Level 3	 Total
Cash and cash equivalents Fixed income securities—available for sale Other invested assets - available for sale Equity Securities Investment in associated companies (not cons.) Derivative asset – at fair value through profit and loss	\$ 62,372 - - - -	\$ 4,146,636 250 - - 25,190	\$	70,852 54,728 15,000 46,694	\$ 62,372 4,146,636 71,102 54,728 15,000 71,884
Total assets carried at fair value	\$ 62,372	\$ 4,172,076	\$	187,274	\$ 4,421,722
Derivative liabilities – at fair value through profit and loss	\$ -	\$ (19,166)	\$	_	\$ (19,166)
Total liabilities carried at fair value	\$ -	\$ (19,166)	\$	-	\$ (19,166)

The following table provides a reconciliation of the fair values of financial instruments included in level 3 at the beginning of the financial year with the fair values as at the end of the financial year.

	2020												
	а	r invested ssets - ilable for sale		Equity curities	ass	stment in sociated mpanies ot cons.)	Derivative asset - at fair value through profit and loss						
Balance as at January 1	\$	70,852	\$	54,728	\$	15,000	\$	46,694					
Additions		4,497		3,550		-		-					
Disposals		-		(8,759)		-		(45,048)					
Unrealised gains with effect on profit and loss		-		-		-		34,882					
Unrealized gains OCI /Realisation OCI		4,157		171		-		-					
Unrealized losses OCI / Realisation OCI				(1,128)		-							
Balance as at December 31	\$	79,506	\$	48,563	\$	15,000	\$	36,527					

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	2019													
	а	r invested issets - ilable for sale		Equity curities	ass	stment in sociated mpanies ot cons.)	Derivative asset - at fair value through profit and loss							
Balance as at January 1	\$	56,767	\$	45,789	\$	14,751	\$	56,778						
Additions		12,490		12,194		2,374		-						
Disposals		(250)		(2,414)		(2,125)		(44,261)						
Unrealised gains with effect on profit and loss		-		-		-		34,178						
Unrealized gains OCI /Realisation OCI		1,845		112		-		-						
Unrealized losses OCI / Realisation OCI				(952)										
Balance as at December 31	\$	70,852	\$	54,728	\$	15,000	\$	46,694						

If models are used to measure financial instruments included in level 3 under which the adoption of reasonable alternative inputs leads to a material change in fair value, IFRS 7 "Financial Instruments: Disclosures" requires disclosure of the effects of these alternative assumptions. The effects of alternative inputs and assumptions are immaterial in respect to the disclosed financial instruments included in level 3.

## Application of the temporary exemption from IFRS 9

The Company met the eligibility criteria for temporary exemption under IFRS 4 from applying IFRS 9 and has accordingly deferred the adoption of IFRS 9. The tables below presents an analysis of the fair value of classes of financial assets as at the end of the reporting period as well as the change in fair value during the reporting period. The classes are defined as follows:

- I. Solely payments of principal and interest ("SPPI"): assets of which cash flows represent solely payments of principal and interest on an outstanding principal amount, excluding any financial assets that meet the definition of held for trading in IFRS 9, or that are managed and whose performance is evaluated on a fair value basis; and
- II. Other at fair value: all financial assets other than those specified in SPPI. Financial assets:
  - a. with contractual terms that do not give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amounts outstanding:
  - b. that meet the definition of held for trading in IFRS 9; or
  - c. that are managed and whose performance are evaluated on a fair value basis.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

				20	)20				
	Fi	nancial asset		•					
		principal a	•		All other financial assets				
			Fa	air value			Fair	r value	
	Fai	r value as of	cha	nge in the	Fair	value as of	chan	ge in the	
	De	cember 31st	fina	ncial year	Dec	ember 31st	finan	cial year	
Fixed income securities -available for sale Other invested assets -available for sale	\$	3,964,976 79,506	\$	226,493 4,157	\$	21,497 -	\$	-	
Derivative linked to insurance risk Equity Securities Short-term investments		- - -		- - -		54,877 48,563 613		- - -	
Total Financial Assets	\$	4,044,482	\$	230,650	\$	125,550	\$	-	

				20	19			
	F	inancial assessolely to pa principal a	aym	ents of		All other fina	ıncial a	assets
Other invested assets -available for sale Derivative linked to insurance risk		r value as of cember 31st	cł	Fair value hange in the nancial year		value as of ember 31st	chan	r value ge in the cial year
Fixed income securities -available for sale Other invested assets -available for sale Derivative linked to insurance risk Equity Securities	\$	4,123,898 70,852 -	\$	275,687 1,845 -	\$	22,738 250 71,884 54,728	\$	- - -
Total Financial Assets	\$	4,194,750	\$	277,532	\$	149,600	\$	_

The above table shows the financial assets that are to be recognized in future in accordance with IFRS 9 and splits them into a group that satisfies the cash flow criterion for financial assets as well as all other financial assets. The latter encompass the financial assets currently measured at fair value through profit or loss that by their very nature cannot fulfil the cash flow criterion enshrined in IFRS 9. The cash flow criterion is met if the contractual conditions of the financial instrument give rise to cash flows at set times that are solely payments of principal and interest (SPPI).

The following table shows the rating structure of financial assets that give rise to solely payments of principal and interest.

	2020	2019
G	ross Value	Gross Value
	1,317,015	1,181,112
	516,078	530,516
	770,453	914,049
	1,264,474	1,432,771
	96,953	65,449
	79,509	70,853
\$	4,044,482	\$ 4,194,750
		1,317,015 516,078 770,453 1,264,474 96,953 79,509

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

The fair value for financial assets that meet the cash flow criterion and have more than a low credit risk corresponds to the carrying amount before impairment shown in the table.

### 8. Participating interest other companies

The participating interest other companies is recognized and measure based on the respective applicable IFRS for this type of asset. The carrying amount of the participating interest other companies is as follows for 2020 and 2019:

#### Investments in associated companies

	2020	2019
Net book value at 31 December of the previous year	15,000	14,751
Additions	-	249
Disposals	-	-
Profit or loss on investments in associated companies	-	-
Dividend payments		-
Net book value at 31 December of the year under review	15,000	15,000

#### 9. Funds withheld

The funds withheld assets totaling \$3.0 billion (2019: \$3.0 billion) represent the cash and securities deposits furnished to the Company by cedants (or by the Company to affiliated cendants with respect to funds held liabilities) that do not trigger any cash flows and cannot be realized by cedants or the Company without consent of the other counter-party. Funds held liabilities totaling \$227.5 million and \$230.5 million for 2020 and 2019 respectively. In the event of default on such a deposit the Company's reinsurance commitment is reduced to the same extent.

#### 10. Contract deposits assets

Contract deposits assets totaling \$293.9 million (2019: \$289.6 million) include consideration paid for acquiring the reinsurance contracts. Insurance contracts are accounted for under the "deposit accounting" method.

#### 11. Derivative receivable and derivative liabilities – at fair value through profit and loss

		20	20		2019								
	D	erivative Assets		Derivative Liabilities		Derivative Assets		Derivative Liabilities					
Derivative instruments Embedded derivatives	\$	36,527 18,350	\$	(29,117)	\$	46,694 25,190	\$	(19,166)					
Total derivatives	\$	54,877	\$	(29,117)	\$	71,884	\$	(19,166)					

#### **Derivative instruments**

Transactions where the Company offers their contracting parties coverage for risks from possible future payment obligations arising out of hedging instruments are also to be classified as derivative financial instruments. The payment obligations result from contractually defined events and relate to the

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

development of an underlying group of primary insurance contracts with statutory reserving requirements. The contracts are to be categorised and recognized as stand-alone credit derivatives pursuant to IAS 39. These derivative financial instruments are carried in Derivative asset - at fair value through profit and loss included in the consolidated balance sheet. The net fair value of these instruments as of December 31, 2020 was \$36.5 million (2019: \$46.7 million).

The Company's derivatives transfer insurance risks and consists of structured transactions that finance statutory reserves (so-called Triple-X or AXXX reserves) of U.S. ceding companies and these transactions are accounted for as derivative financial instruments under IAS39.

Details of the structured transactions at December 31, 2020 and 2019 are the following (amounts in \$ millions):

						2020		
Transaction No.	Effective Date	Initial Term (years)		Notional Value	 Peak Notional Value	 Fair Value Asset	 Fair Value Liability	 Fair Value Net
1	7/31/2014	15		\$ 1,290	\$ 1,512	\$ 9	\$ 9	\$ _
2	9/30/2014	25		899	1,110	57	32	25
3	12/12/2014	20		72	107	2	2	-
4	2/18/2015	20		225	1,000	28	28	-
5	12/31/2016	15		208	208	2	2	-
6	3/29/2017	20		733	1,000	5	5	-
7	6/29/2017	20		371	500	4	4	-
8	7/1/2017	15		927	1,020	25	13	12
9	7/27/2018	20		677	900	5	5	-
10	9/30/2019	15	_	333	 411	 3	 3	 -
		7	Total	\$ 5,735	\$ 7,768	\$ 140	\$ 103	\$ 37

			2019									
Transaction No.	Effective Date	Initial Term (years)		lotional Value		Peak Notional Value	F	air Value Asset		air Value Liability	F	air Value Net
1	07/31/14	15	\$	1,137	\$	1,512	\$	14	\$	14	\$	-
2	09/30/14	25		872		1,110		59		32		27
3	12/12/14	20		71		107		2		2		-
4	02/18/15	20		25		1,000		27		27		-
5	01/15/16	18		738		738		8		8		-
6	12/31/16	15		242		242		2		2		-
7	03/29/17	20		733		1,000		7		7		-
8	06/29/17	20		394		500		5		5		-
9	07/01/17	15		971		1,020		38		18		20
10	07/27/18	20		738		900		7		7		
11	09/30/19	15		202		411		3		3		-
		Tota	I \$	6,123	\$	8,540	\$	172	\$	125	\$	47

The fair value of the above derivatives are calculated using a discounted cash flow method, representing the present value of expected future cash flows from fee revenue over a reasonable estimated period discounted at the risk free term structure of U.S. dollar forward rates (based on swaps) prevailing at the time of the valuation. These fair value amounts are recognized as a derivative receivable at fair value through profit and loss and derivative liabilities at fair value through profit and loss on the balance sheet. The change in value in subsequent periods is dependent upon the risk experience. Income recognized under these contracts is \$24.9 million (2019: \$15.0 million) and reflected in Ordinary investment income on the Statements of Income.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

Transaction	Maturity	2020 al Return Swap	Tot	2019 Total Return Swap				
1	July 15, 2028	\$ 3,437	\$	3,958				
2	February 15, 2042	25,680		15,208				
		\$ 29,117	\$	19,166				

In February 2019, the Company entered into two derivative transactions with an affiliate, Hannover Ruck Se, which are total return swaps. Under the total return swap agreements, the performance of the Company's investments in U.S. Treasury Inflation Protected Securities ("TIPS") is exchanged for the performance of an equivalent notional amount of U.S. Treasury Bonds ("USTB") having similar maturity dates. Settlements between the parties are made semi-annually for differences in the investment performance of the TIPS and the USTB.

The Company holds \$120.0 million par value of TIPS having a contractual maturity date of July 15, 2028 and \$100.0 million par value of TIPS having a contractual maturity date of February 15, 2042. During 2020, the Company received settlement payments of \$4.6 million under the total return swap agreement for the TIPS maturing in 2028 and the Company made net settlement payments of \$1.4 million under the total return swap agreement for the TIPS maturing in 2042. At December 31, 2020, the Company recognized a liability of \$3.4 million and \$25.7 million from the fair values of the total return swap agreement for the TIPS maturing in 2028 and 2042, respectively.

During 2019, the Company made a settlement payment of \$657 thousand under the total return swap agreement for the TIPS maturing in 2028 and the Company received \$1.3 million from settlement payments under the total return swap agreement for the TIPS maturing in 2042. At December 31, 2019, the Company recognized a liability of \$4.0 million and \$15.2 million from the fair values of the total return swap agreement for the TIPS maturing in 2028 and 2042, respectively.

#### **Embedded derivative**

A number of treaties meet criteria which require the application of the prescriptions in IFRS 4 'Insurance Contracts' governing embedded derivatives. These accounting regulations require that certain derivatives embedded in reinsurance contracts be separated from the underlying insurance contract ("host contract"), reported separately at fair value in accordance with IAS 39 'Financial Instruments: Recognition and Measurement' and recognized under investments. Fluctuations in the fair value of the derivative components are to be recognized in income in subsequent periods.

Within the scope of the accounting of "modified coinsurance" (ModCo) and "coinsurance funds held" (CoFWH) reinsurance treaties, under which securities deposits are held by the ceding companies and payments rendered on the basis of income from certain securities of the ceding company, the interest rate risk elements are clearly and closely related to the underlying reinsurance agreements. Embedded derivatives consequently result solely from the credit risk of the underlying securities portfolio.

The Company calculates a fair value for the embedded derivative in ModCo and CoFWH treaties using market information available for the underlying securities on the valuation date on the basis of a "credit spread" method. Under this method the derivative is valued at zero on the date the contract

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

commences and its value then fluctuates over time according to changes in the credit spread of the underlying securities.

The cumulative value of the derivative is shown in the Balance Sheets under derivative liabilities with the movement reported in the Statement of Income as an unrealized gain/(loss) on investments. The unrealized loss for the year totaled \$6.8 million (2019: \$8.9 million unrealized gain).

## 12. Accounts receivable & accounts payable

For further explanatory remarks please see section 4.1 'Summary of major accounting policies'. All amounts presented in the balance sheet at amortized cost approximate to fair value.

## 13. Deferred acquisition costs (DAC)

In life and health reinsurance, the deferred acquisition costs associated with life and annuity policies with regular premium payments are determined in light of the period of the contracts, the expected surrenders, the lapse expectancies and the anticipated interest income.

The following table shows the DAC development for 2020 and 2019:

	 2020	2019				
Net book Value at January 1	\$ 430,375	\$	440,523			
Additions	55,556		58,933			
Amortisations	 (45,376)		(69,082)			
Net book Value at December 31	\$ 440,555	\$	430,375			

#### 14. Other assets and liabilities

Other assets totaling \$11.2 million (2019: \$14.4 million) and other liabilities totaling \$144.2 million (2019: \$199.8 million) consists of the following at December 31, 2020 and 2019:

		asse	ts	
		2020		2019
Prepaid reinsurance premiums	\$	-	\$	4
Advances paid		386		1,117
Office equipment		556		1,545
Real estate used for own purposes		6,882		9,453
Prepaid expenses		546		-
Accrued interest and rent		891		1,103
Other receivables		1,915		1,212
Total	\$	11,176	\$	14,434

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	Other liabilities								
			2019						
Provision share awards	\$	6,324	\$	8,296					
Holiday, bonuses and overtime		9,107		8,316					
Accrued interest		11,563		11,458					
Other accrued and deferred items		97,972		102,189					
Contract liabilities - IFRS 15		8,889		9,444					
Lease liabilities		7,275		9,755					
Income tax payable		-		4,083					
Other liabilities		3,116		46,293					
Total	\$	144,246	\$	199,834					

#### 15. Contract deposit liabilities, benefit & claims reserves

In order to show the net reinsurance provisions remaining in the retention the following table compares the gross provisions with the corresponding retrocessionaires' shares, which are shown as assets in the balance sheet.

		2020		2019						
	Gross	Retro	 Net		Gross		Retro		Net	
Benefit reserves Contract Deposit Liabilities	\$ 1,979,851 2.549.501	\$ 182,205	\$ 1,797,646 2.549.501	\$	2,137,582 2.545.040	\$	191,023	\$	1,946,559 2,545,040	
Total	\$ 4,529,352	\$ 182,205	\$ 4,347,147	\$	4,682,622	\$	191,023	\$	4,491,599	

#### **Maturities of reinsurance reserves**

IFRS 4 "Insurance Contracts" requires information which helps to clarify the amount and timing of cash flows expected from reinsurance contracts. In the following tables we have shown the future maturities of the technical provisions broken down by the expected remaining times to maturity. As part of our maturity analysis we have directly deducted the deposits put up as collateral for these reserves, since the cash inflows and outflows from these deposits are to be allocated directly to the ceding companies. For further explanation of the recognition and measurement of the reserves please see Note 4 "Summary of significant accounting policies."

	2020							2019						
	Gross		Retro		Net		Gross		Retro		Net			
Due in one year	\$	358,368	\$	11,616	\$	346,752	\$	321,603	\$	10,657	\$	310,946		
Due one through five years		1,016,287		39,610		976,677		1,063,313		28,237		1,035,076		
Due five through ten years		745,020		39,398		705,622		823,224		12,979		810,245		
Due ten through twenty years		944,457		53,805		890,652		862,157		57,589		804,568		
Due after twenty years		1,465,220		37,776		1,427,444		1,612,325		81,561		1,530,764		
Total	\$	4,529,352	\$	182,205	\$	4,347,147	\$	4,682,622	\$	191,023	\$	4,491,599		

Benefit reserves are established to meet the expected liability to cedants arising from future claims. Profit commission reserves are established to meet the expected liability to cedants arising from future profit commission payments. Deferred acquisition costs are described in note 13. Benefit reserves; profit commission reserves and DAC are calculated using a net premium valuation methodology, as required under provisions of US GAAP.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

The reserving basis is based on prospective actuarial assumptions relating to mortality, morbidity, persistency, expenses and future interest rate development. Bases are determined using current best estimate with a provision for adverse deviation in future experience.

In accordance with US GAAP, valuation assumptions for FAS60 business are locked in at outset and are not unlocked unless a loss recognition event occurs. Loss recognition is assessed annually by determining the expected future profits on the current best estimate assumption bases. In accordance with this assessment, there is no loss recognition event during 2020.

The adequacy of the reinsurance liabilities arising out of our reinsurance treaties is reviewed as at each balance sheet date. In the context of the adequacy testing of reinsurance liabilities (liability adequacy test pursuant to IFRS 4 in conjunction with loss recognition test as per US GAAP) the anticipated future contractual payment obligations are compared with the anticipated future income. Should the result of the test indicate that the anticipated future income will not be sufficient to fund future payments; the entire shortfall is recognised in income by first writing off capitalised acquisition costs corresponding to the shortfall. Any remaining difference is constituted as an additional provision.

## **Development of benefit reserves**

A rollforward of reinsurance reserves is as follows:

	2020							2019						
	Gross			s Retro		Net		Gross		Retro		Net		
Balance as at January 1	\$	4,682,622	\$	191,023	\$	4,491,599	\$	4,873,482	\$	131,812	\$	4,741,670		
Current year development Portfolio entries/withdrawals		(153,270) -		(8,818) -		(144,452) -		32,808 (223,668)		59,211 -		(26,403) (223,668)		
Balance as at December 31	\$	4,529,352	\$	182,205	\$	4,347,147	\$	4,682,622	\$	191,023	\$	4,491,599		

#### **Development of claims reserves**

The claims reserves are in principle calculated on the basis of the information supplied by ceding companies. The development of the claims reserves is shown in the following table:

			2020			2019						
	Gross	Retro		Net		Gross		Retro			Net	
Balance as at January 1	\$ 1,209,096	\$	91,201	\$	1,117,895	\$	1,122,687	\$	74,588	\$	1,048,099	
Current year development Portfolio entries/withdrawals	 43,214 -		(25,237)		68,451 -		86,112 297		13,418 3,195		72,694 (2,898)	
Balance as at December 31	\$ 1,252,310	\$	65,964	\$	1,186,346	\$	1,209,096	\$	91,201	\$	1,117,895	

Claims with a Covid-19 cause of death increased the losses on the year-end December 31, 2020 by \$166.2 million.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 16. Loans and borrowings

The following table provides a listing of the subordinated loans held by the Company as of December 31, 2020.

Lender	Principal ('000s)		Interest Rate	Inception	Maturity	Inter	rest accrued ('000)	erest paid t year ('000s)
Hannover Finance, Inc.	\$	2,500	6.67%	March 17, 2014	March 17, 2054	\$	85	\$ 170
Hannover Ruck		238,000	4.60%	March 27, 2018	April 15, 2038		5,596	5,535
Hannover Finance, Inc.		75,000	4.20%	September 30, 2020	September 30, 2040		1,438	2,859
Hannover Ruck		50,000	3.58%	September 22, 2016	September 22, 2046		915	1,820
Hannover Ruck		75,000	4.60%	December 23, 2016	December 23, 2046		1,763	3,508
Hannover RE (Ireland)		5,000	3.32%	January 20, 2016	March 15, 2065		85	169
Hannover RE (Ireland)		5,000	3.48%	July 1, 2016	March 15, 2065		89	 177
	\$	450,500				\$	9,970	\$ 14,237

The carrying amounts of the loans are close approximation of their fair value, which is estimated at December 31, 2020 and 2019 to be \$450.5 million. All principal payments are only due upon maturity.

#### 17. Shareholders equity

The "common shares" of the Company amount to 2.5 million shares of \$1 par value each. Unrealized gains and losses from the fair value measurement of financial instruments held as available for sale are carried in accumulated other comprehensive income of \$350.0 million (2019: \$188.0 million).

On September 30, 2019 the Company declared an ordinary stockholder dividend to its parent in the amount of \$27.0 million payable on May 2020.

On December 30, 2019 the Company paid an ordinary stockholder dividend to its parent in the amount of \$14.7 million.

On December 30, 2019 the Company issued a short-term note payable to its parent in the amount of \$14.7 million. The note was paid on April 3, 2020.

On February 18, 2020 the Company paid an ordinary stockholder dividend to its parent in the amount of \$40.3 million.

On February 18, 2020 the Company issued a short-term note payable to its parent in the amount of \$40.3 million. The note was paid on April 3, 2020.

On September 15, 2020 the Company paid an ordinary stockholder dividend to its parent in the amount of \$11.8 million.

On November 12, 2020 the Company paid an ordinary stockholder dividend to its parent in the amount of \$7.0 million.

## 18. Gross written premium

Gross written premium was \$1.9 billion (2019: \$2.1 billion) for the period ended December 31, 2020 and originates from cedants based in the United States of America.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 19. Investment income

Net investment income was \$294.3 million (2019: \$262.1 million) for the period ended December 31, 2020 and consists of the following components:

	 2020	 2019
Interest Income <sup>2</sup>	\$ 151,557	\$ 157,813
Ordinary investment income	151,557	157,813
Realised gains on investments	89,913	25,788
Realised losses on investments	(7,243)	(5,035)
Unrealized (losses) and gains on investments	(6,839)	8,896
Insurance derivative income	24,930	15,011
Other investment expenses	 (8,780)	 (6,823)
Net income from assets under own management	243,538	195,650
Interest income on funds withheld and contract deposits	179,079	147,958
Interest expense on funds withheld and contract deposits	 (128,304)	 (81,530)
Net investment income	\$ 294,313	\$ 262,078

<sup>&</sup>lt;sup>2</sup> Interest Income from Fixed - income securities - available for sale

An impairment loss was recognized of \$1.7 million on fixed income securities in the year under review.

The net gains and losses on financial assets/liabilities are shown in the following table.

	2020												
		Ordinary investment income		Realised gains and losses		Unrealised gains and losses	Investment expenses			Insurance derivative income		Net income from assets under own management	
Available for sale– Fixed income securities At fair value through profit and loss		151,557	\$	82,670	\$	-	\$	(8,780)	\$	-	\$	225,447	
Derivative assets		-		-		(6,839)				24,930		18,091	
Total	\$	151,557	\$	82,670	\$	(6,839)	\$	(8,780)	\$	24,930	\$	243,538	

	2019										
	Ordinary investment income		Realised gains and losses		Unrealised gains and losses		Investment expenses		Insurance derivative income		let income from ssets under own management
Available for sale– Fixed income securities At fair value through profit and loss	\$ 157,813	\$	20,753	\$	-	\$	(6,823)	\$	-	\$	171,743
Derivative assets	_		-		8,896				15,011	_	23,907
Total	\$ 157,813	\$	20,753	\$	8,896	\$	(6,823)	\$	15,011	\$	195,650

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 20. Other income and expenses

Other income and expenses totaled \$299.8 million (2019: \$260.7 million) and consists of the following:

	2020		 2019	
Other income				
Income from contracts recognised in accordance with				
the deposit accounting method	\$	272,256	\$ 272,275	
Other interest income relating to financial guarantees		37,844	9,473	
Other income		16,168	 21,694	
Total other income		326,268	 303,442	
Other expenses				
Expenses from contracts recognised in accordance with				
the deposit accounting method		(16,073)	(33,316)	
Sundry expenses		(10,442)	(9,437)	
Total expenses		(26,515)	 (42,753)	
Total other income and expenses	\$	299,753	\$ 260,689	

#### Financial guarantees

The Company has entered into a structured transaction in order to finance statutory reserves (so-called Triple-X or AXXX reserves) of a U.S. ceding company and the Company has entered into two swap agreements with an affiliate in support of secured note obligations collateralized by underlying insurance commission streams. These transactions are accounted for as a Financial Guarantee under IAS39.

Details of structured transactions that are accounted as financial guarantees at December 31, 2020 and 2019 are as follows (amounts in \$ millions):

Transaction No.	Effective Date	Initial Term (years)	Notional Value at December 2020		V	otional alue at cember 2019
1	4/1/2014	20	\$	_	\$	798.2
2	3/14/2016	13		21.6		26.4
		Total	\$	21.6	\$	824.6

The client terminated effective April 1, 2020 Transaction #1 and the Company received termination fee on the amount of \$32.8 million.

Under IAS 39 these transactions are recognized at fair value as a financial guarantee. To this end the Company uses the net method, according to which the present value of the agreed fixed swap premiums is netted with the present value of the guarantee commitment. The fair value on initial recognition therefore amounted to zero. The higher of the fair value and the amount carried as a provision on the liabilities side pursuant to IAS 37 is recognized at the point in time when utilization is

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

considered probable. This was not the case as at the balance sheet date. The fee income of \$37.8 million (2019: \$9.5 million) is included in Other income and expenses on the Statements of Income.

The probability of a loss to the Company on these transactions involving ceding special purpose entities as contracting parties from which the Company assumes certain underwriting and /or financial risks is categorised as low. The transactions largely serve the purpose of financing statutory reserves (so-called Triple-X or AXXX reserves) and transferring extreme mortality risks above a contractually defined retention. Since the Company does not bear the majority of the economic risks or benefits arising out of its business relations with these special purpose entities and cannot exercise a controlling influence over them, there is no consolidation requirement for the Company. Depending upon the classification of the contracts pursuant to IAS 39, the transactions are recognized either as derivative financial instruments or as financial guarantees. In addition, the Company cedes all of the risk of payment under the derivative contracts to affiliates.

#### 21. Taxes

Corporation tax is provided based on the profit or loss for the year. The Company is subject to USA corporation tax on qualifying trading operations at a rate of 21%. Corporation tax is recognized in the Statements of Comprehensive Income as part of the profit or loss.

Under current Bermuda law the Company is not required to pay any taxes in Bermuda on either income or capital gains. The Company made an irrevocable election under Section 953(d) of the U.S. Internal Revenue Code of 1986, as amended, to treat the Company as a domestic insurance company for U.S. federal income tax purposes. As such, the Company will be subject to U.S. federal income tax on its income as if it is a U.S. corporation.

A deferred tax asset is recognized in respect of temporary differences between the carrying amount of assets and liabilities for condensed financial reporting purposes and the amounts used for taxation purposes. The deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, using tax rates enacted at the reporting date. Deferred tax assets are netted against deferred tax liabilities where there is a legally enforceable right to offset current tax liabilities and assets, and they relate to taxes levied by the same tax authority on the same taxable entity. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

The breakdown of actual and deferred income taxes was as follows:

		2019		
Actual tax for the year under review	\$	(43,727)	\$	23,338
Deferred taxes due to temporary differences		60,351		26,812
Total	\$	16,624	\$	50,150

Current income taxes receivable at December 31, 2020 \$33.8 million (2019: income tax payable \$4.1 million). The following table presents a breakdown of the deferred tax assets and liabilities into the balance sheet items from which they are derived.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

	2020		 2019	
Deferred tax assets				
Derivative assets	\$	41,152	\$ 6,744	
Net operating losses		252,182	322,430	
Investments		-	37,371	
General expenses		3,449	3,518	
Compensation		3,084	3,398	
Sundry items		345	349	
Total deferred tax assets		300,213	373,810	
Deferred tax liabilities				
Investments		(80,842)	-	
Deferred acquisition costs		(62,048)	(52,442)	
Liabilities from reinsurance business		(422, 339)	(482,312)	
Depreciable fixed assets		(1,543)	(2,196)	
Total deferred tax liabilities		(566,772)	 (536,949)	
Net deferred tax liability	\$	(266,559)	\$ (163,139)	

HLRA Ber files a separate federal income tax return and HLRUS files a consolidated federal income tax return with Sand Lake Re, Inc. The net deferred tax liabilities of \$266.6 million include deferred tax assets in an amount of \$252.2 million that relates to carried forward tax losses, of which \$94.3 million belongs to HLRUS/SLRe tax return filing group and \$157.8 million belongs to HLRA Ber. During 2018, both tax return filing groups incurred tax losses following the recapture of all retrocessions from foreign affiliates retroactive to January 1, 2018. The recapture transaction that gave rise to the loss is not recurring. In addition, management believes that sufficient taxable temporary differences and future taxable profits will continue to be available to offset the carried forward tax losses for both tax return filing groups. As such, the Company concluded that it is more likely than not that the deferred tax assets will be fully recoverable in the future.

Currently, there are no tax contingency accruals established pursuant to IAS 12.

The amount of tax cumulatively charged to other comprehensive income includes \$93.0 million for unrealized gains on available-for-sale securities. (2019: \$50.0 million).

The reconciliation of expected income tax expense with the actual expense is as follows:

	2020			2019		
Profit before taxes on income	\$	24,729	\$	49,792		
CARES Act carryback rate benefit		(8,214)		-		
Nondeductible expenses		179		210		
Other		(69)		150		
Actual expense for income taxes	\$	16,624	\$	50,152		

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

#### 22. Related party disclosures

The Company reinsures life assurance business written by its client companies (cedants) and business assumed from affiliates. The risks assumed generally reflect the risks inherent in the underlying life assurance policies and include mortality risk, morbidity risk, investment risk and lapse and surrender risk. The Company also assumes life insurance risk in alternative forms, including capital market risks.

	2020						2019					
Income statement	Hannover Finance, Inc. (Parent)	rela	ompanies ted through mon control		Total		Hannover Finance, Inc. (Parent)	rela	ompanies ted through imon control		Total	
Net Premium Earned Net Investment Income Total Revenues	\$ - -	\$	(32,331) (11,557) (43,888)	\$	(32,331) (11,557) (43,888)	\$	- - -	\$	64,698 (23,050) 41,648	\$	64,698 (23,050) 41,648	
Total Expenses Other income (expenses) Finance Costs	368 1,249 (3,115)		4,830 (34) (16,987)		5,198 1,215 (20,102)		350 1,575 (3,008)		7,701 (907) (16,759)		8,051 668 (19,767)	
Net income/(loss)	\$ (1,498)	\$	(56,079)	\$	(57,577)	\$	(1,083)	\$	31,683	\$	30,600	

2020							2019						
<b>-</b>	Finance, re			Companies related through			Hannover Finance,		Companies related through				
Balance sheet	Inc	. (Parent)	com	mon control		Total	Inc	. (Parent)	com	ımon control		Total	
Reinsurance Assets Reinsurance liabilities Loans and borrowings	\$	242 - (80,615)	\$	(21,897) (9,166) (381,448)	\$	(21,655) (9,166) (462,063)	\$	295 - (80,508)	\$	(24,060) (9,208) (381,450)	\$	(23,765) (9,208) (461,958)	

All transactions and balances arise from the normal course of business and are unsecured.

#### 23. Other investment expenses

The Company has an investment management agreement in place with a related party to manage the Company's investment portfolio. Investment management fees incurred during the year amounted to \$8.8 million (2019: \$6.8 million).

#### 24. Statutory requirements

As a Class E insurer, the Company must at all times maintain a solvency margin and an enhanced capital requirement in accordance with the provisions of the Insurance Act. Each year the Company is required to file with the Bermuda Monetary Authority (the "Authority") a capital and solvency return within four months of its relevant financial year end (unless specifically extended).

The prescribed form of capital and solvency return, primarily comprises the Insurer's Statutory Financial Return, Bermuda Solvency Capital Requirement ("BSCR"), and associated schedules including Form 4 EBS and various other schedules as prescribed in the 1978 Act, The Insurance Accounts Rules 2016, The Insurance (Prudential Standards) (Class C, Class D and Class E Solvency Requirement) Rules 2011, Insurance (Eligible Capital) Rules 2012, and Insurance (Public Disclosure) Rules 2015. The BSCR includes a standardized model used to measure the risk associated with an insurer's assets, liabilities and premiums, and a formula to take account of insurance related risk exposure. The Minimum Margin of Solvency ("MMS") is calculated on predetermined calculations as included The Insurance Accounts Rules 2016.

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

Insurers Enhanced Capital Requirements ("ECR") is calculated as the higher of the capital requirements as measured by the BSCR and MMS. The Authority requires all Class E insurers to maintain their capital at a target level which is 120% of ECR.

As at December 31, 2020 the Company's statutory capital and reserves exceeded all calculated minimum regulatory requirements.

The Company is prohibited from declaring or paying a dividend if its Class E statutory capital and surplus is less than its ECR, or if it is in breach of its solvency margin, or if the declaration or payment of such dividend would cause such breach. Further, the Company, as a Class E insurer, is prohibited from declaring or paying any dividend of more than 25% of its total statutory capital and surplus, (as shown on its statutory balance) unless it files (at least seven days before payment of such dividends) with the BMA an affidavit stating that it will continue to meet its relevant margins. The Company must obtain the BMA's prior approval for a reduction by 15% or more of the total statutory capital as set forth in its previous year's financial statements. These restrictions on declaring or paying dividends and distributions under the Insurance Act are in addition to those under the Companies Act 1981, which apply to all Bermuda companies.

Actual statutory capital and surplus, as determined using statutory accounting principles, along with a reconciliation to IFRS equity is as follows:

	 2020
Total statutory capital and surplus Non admitted assets	\$ 2,686,508
Statutory capital and surplus	 2,686,508
Surplus Note	 (315,500)
Total IFRS Shareholder's equity	\$ 2,371,008

#### 25. Capital management

The preservation and consistent enhancement of its capital is a key strategic objective for the Company. The Company satisfies the capital expectations of the rating agencies that assess its financial strength. The Company met the applicable local minimum capital requirements in the year under review. The parent company ensures that the local minimum capital requirements applicable to subsidiaries are always satisfied in accordance with the official requirements defined by insurance regulators.

#### 26. Other Notes

#### 26.1 Expenditures on personnel

The expenditures on insurance business, claims expenses (claims settlement) and expenditures on the administration of investments include the following personnel expenditures:

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

in USD thousands	2020		2019	
Wages and salaries	\$	45,667	\$	45,601
Social security contributions and expenditure on provision and assistance				
Social security contributions	\$	2,745	\$	2,506
Expenditure for pension provision		4,563		4,132
Expenditure for assitance		4,723		4,275
		12,031		10,913
Total personnel expenditures	\$	57,698	\$	56,514

## 26.2 Defined contribution plan

The Company have a defined contribution plan based on length of service and the employee's income or level of contributions. The expense recognized for these obligations in the financial year in accordance with IAS 19 "Employee Benefits" was \$4.6 million (2019: \$4.1 million).

#### 26.3 Leases

The Company leases various office premises, technical facilities and office equipment. The following items were recognized in the consolidated balance sheets as of December 31, 2020 in other assets and other liabilities in connection with the leases:

Leases in the Balance Sheets	 2020	2019		
Own-use real estate	\$ 12,047	\$	12,056	
Fixtures, fitting and equipment	\$ 86	\$	86	
Lease liabilities	\$ 7,275	\$	9,755	

The following amounts were recognized in the consolidated statement of income in administrative expenses in connection with the leases:

#### Amortization of right-of-use assets in

connection with leases	 2020	2019			
Own-use real estate	\$ 2,563	\$	2,603		
Fixtures, fitting and equipment	37		49		
Total	\$ 2,600	\$	2,652		

The interest expenses for lease liabilities for 2020 totaled \$258 thousand and \$332 thousand for 2019. The total amounts payable for leases in 2020 came to \$7.3 million (2019: \$9.8 million).

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

The Company holds four leases at the end of December 31, 2020, the last one is set to expire by August 2024.

Future minimum lease payments	Amounts		
2021	\$	2,709	
2022		2,177	
2023		2,230	
2024		541	
2025		-	
Subsequent years			
	\$	7,657	

#### 26.4 Assets on Deposit or Pledge as Collateral

As security for technical liabilities, the Company has established trust accounts, the securities held in the trust accounts are shown as available-for-sale investments and participating interest in other companies in the balance sheet. At December 31, 2020 and 2019, the amounts were as follows:

#### Assets on Deposit or Pledge as Collateral

Assets on Deposit or Pleage as Collate	raı						
	December 31, 2020 Gross Restricted						
	Total General Account Current Year		Total from Prior Year		Increase (Decrease)		
Asset Category							
On deposit with states	\$	2,720	\$	2,487	\$	233	
FHLB Capital Stock		15,000		15,000		-	
Pledged as reinsurace collateral - bonds		232,972		301,136		(68, 164)	
Total restricted assets	\$	250,692	\$	318,623	\$	(67,931)	
		D	ecemb	er 31, 2019			
	Gross Restricted						
	Total General Account Current Year		Total from Prior Year		Increase (Decrease)		
Asset Category							
On deposit with states	\$	2,487	\$	2,293	\$	194	
FHLB Capital Stock		15,000		14,751		249	
Pledged as reinsurace collateral - bonds		301,136		346,989		(45,852)	
Total restricted assets	\$	318,624	\$	364,032	\$	(45,409)	

#### 27. Subsequent events

Management has evaluated subsequent events through the date of the issuance of these financial statements, May 3, 2021, and other than as discussed below, determined that there were no events or transactions during this period that were required to be recorded or disclosed in the financial statements.

In January 2021, a cedant of the company disposed of parts of its life insurance portfolio. In this context it was possible to partially dissolve or reorganize the collateralization structures that had been put in

Notes to the Consolidated Financial Statements

For the years ended December 31, 2020 and 2019 (Expressed in thousands of US Dollars, unless noted in millions)

place by the Parent Company in connection with the reinsurance of this portfolio. This restructuring resulted in a profit contribution in the order of \$156.1 million before tax in the first quarter of 2021.

The financial statements have been approved by the Management on May 3, 2021.